{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:58:20Z","timestamp":1772161100057,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,6,2]],"date-time":"2013-06-02T00:00:00Z","timestamp":1370131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s10067-013-2303-6","type":"journal-article","created":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T03:53:30Z","timestamp":1370058810000},"page":"1451-1458","source":"Crossref","is-referenced-by-count":16,"title":["Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic\u2014data from the ATTRA registry"],"prefix":"10.1007","volume":"32","author":[{"given":"Pavel","family":"Hor\u00e1k","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Sk\u00e1celov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Hejduk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Smr\u017eov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,2]]},"reference":[{"key":"2303_CR1","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer JM, Westhovens R, Leon M et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907\u20131915","journal-title":"N Engl J Med"},{"key":"2303_CR2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"PS Linsley","year":"1991","unstructured":"Linsley PS, Brady W, Urnes M et al (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561\u2013569","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"2303_CR3","first-page":"263","volume":"63","author":"D Tegzov\u00e1","year":"2004","unstructured":"Tegzov\u00e1 D, Vencovsky J, Dusek L, Pavelka K (2004) Clinical register of TNF alpha blocking therapy of Czech rheumatologic society. Project ATTRA. Results of study: clinical efficacy and safety. Ann Rheum Dis 63(Suppl 1):263","journal-title":"Ann Rheum Dis"},{"key":"2303_CR4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"MLL Prevoo","year":"1995","unstructured":"Prevoo MLL, van \u2018t Hof MA, Kuper HH et al (1995) Modified disease activity scores that includes twenty eight- joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348","journal-title":"Arthritis Rheum"},{"key":"2303_CR5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM Gestel Van","year":"1996","unstructured":"Van Gestel AM, Prevoo MLL, van \u2018t Hof MA (1996) Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 39:34\u201340","journal-title":"Arthritis Rheum"},{"key":"2303_CR6","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/rheumatology\/35.11.1101","volume":"35","author":"MLL Prevoo","year":"1996","unstructured":"Prevoo MLL, van Gestel AM, van \u2018t Hof MA et al (1996) Remission in a prospective study of patients with rheumatoid arthritis. Br J Rheumatol 35:1101\u20131105","journal-title":"Br J Rheumatol"},{"key":"2303_CR7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"key":"2303_CR8","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bmj.306.6890.1437","volume":"306","author":"C Jenkinson","year":"1993","unstructured":"Jenkinson C, Coulter A, Wright L (1993) Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 306:1437\u20131440","journal-title":"BMJ"},{"key":"2303_CR9","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780261107","volume":"26","author":"T Pincus","year":"1983","unstructured":"Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP (1983) Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26:1346\u20131353","journal-title":"Arthritis Rheum"},{"key":"2303_CR10","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","volume":"52","author":"JM Kremer","year":"2005","unstructured":"Kremer JM, Dougados M, Emery P et al (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:2263\u20132271","journal-title":"Arthritis Rheum"},{"key":"2303_CR11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant H, Moreland L et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865\u2013876, 2006","journal-title":"Ann Intern Med"},{"key":"2303_CR12","author":"GR Burmester","year":"2012","unstructured":"Burmester GR (2012) Remission. Nat Rev Rheumatol. doi: 10.1038\/nrrheum.2011.201 [Epub ahead of print]","journal-title":"Nat Rev Rheumatol"},{"key":"2303_CR13","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor in inhibition. N Engl J Med 353:1114\u20131123","journal-title":"N Engl J Med"},{"issue":"Suppl 9","key":"2303_CR14","first-page":"247","volume":"54","author":"MC Genovese","year":"2006","unstructured":"Genovese MC, Schiff M, Luggen M et al (2006) Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. Arthritis Rheum 54(Suppl 9):247","journal-title":"Arthritis Rheum"},{"key":"2303_CR15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/ard.2008.092577","volume":"68","author":"M Dougados","year":"2009","unstructured":"Dougados M, Schmidely N, Le Bars M et al (2009) Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis 68:484\u2013489","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"2303_CR16","first-page":"46","volume":"47","author":"R Westhovens","year":"2008","unstructured":"Westhovens R, Luggen M, Russell A et al (2008) Abatacept provides durable improvements in RA disease status and a consistent safety profile through 3 years in the aim and attain trials. Rheumatology 47(Suppl 2):46","journal-title":"Rheumatology"},{"issue":"Suppl 2","key":"2303_CR17","first-page":"48","volume":"47","author":"P Emery","year":"2008","unstructured":"Emery P, Kremer JM, Moreland R et al (2008) Long-term efficacy and safety of abatacept through 5 years of treatment in rheumatoid arthritis patients with an inadequate response to methotrexate. Rheumatology 47(Suppl 2):48","journal-title":"Rheumatology"},{"key":"2303_CR18","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/ard.2010.139345","volume":"70","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Russell AS, Emery P et al (2011) Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 70:1826\u20131830","journal-title":"Ann Rheum Dis"},{"key":"2303_CR19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10067-009-1363-0","volume":"29","author":"M Schiff","year":"2010","unstructured":"Schiff M, Bessette L (2010) Evaluation of abatacept in biologic-na\u00efve patients with active rheumatoid arthritis. Clin Rheum 29:583\u2013589","journal-title":"Clin Rheum"},{"key":"2303_CR20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2147\/tcrm.2006.2.4.365","volume":"2","author":"EM Vital","year":"2006","unstructured":"Vital EM, Emery P (2006) Abatacept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2:365\u2013375","journal-title":"Ther Clin Risk Manag"},{"key":"2303_CR21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2006.057018","volume":"66","author":"AS Russel","year":"2007","unstructured":"Russel AS, Wallenstein GV, Li T et al (2007) Abatacept Improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 66:189\u2013194","journal-title":"Ann Rheum Dis"},{"key":"2303_CR22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22\u201332","journal-title":"Arthritis Rheum"},{"key":"2303_CR23","unstructured":"van Riel PL, van de Laar MA Evaluation and monitoring of biologicals in the treatment of rheumatoid arthritis in daily clinical practive. DREAM, Report Winter 2011\/2012, Feb 2012, 1\u201339, unpublished data"},{"issue":"Suppl 3","key":"2303_CR24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/annrheumdis-2012-eular.2662","volume":"71","author":"S Lindblad","year":"2012","unstructured":"Lindblad S, Stawiarz L, Swedish Rheumatology Quality Registry (2012) Gender and prevoius treatment influence outcomes from abatacept in a 5 years cohort of rheumatoid arthritis. Ann Rheum Dis 71(Suppl 3):383, Abstract","journal-title":"Ann Rheum Dis"},{"key":"2303_CR25","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1136\/ard.2010.140129","volume":"70","author":"HC Leffers","year":"2011","unstructured":"Leffers HC, Osterggard M, Glintborg B et al (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70:1216\u20131222","journal-title":"Ann Rheum Dis"},{"key":"2303_CR26","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096\u20131103","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"2303_CR27","first-page":"43","volume":"54","author":"M Schiff","year":"2006","unstructured":"Schiff M, Keiserman M, Codding C et al (2006) The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: results from a 1-year double-blind, randomized, placebo-controlled trial. Arthritis Rheum 54(Suppl 1):43","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"2303_CR28","first-page":"89","volume":"66","author":"M Schiff","year":"2007","unstructured":"Schiff M, Pritchard C, Teng J et al (2007) The safety of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: results from the ARRIVE trial. Ann Rheum Dis 66(Suppl 2):89","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 9","key":"2303_CR29","first-page":"786","volume":"58","author":"A Smitten","year":"2008","unstructured":"Smitten A, Simon R, Qi K et al (2008) Hospitalized infections in the abatacept RA clinical development program: an epidemiological assessment with >10,000 person-years of exposure. Arthritis Rheum 58(Suppl 9):786\u2013787","journal-title":"Arthritis Rheum"},{"key":"2303_CR30","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","volume":"54","author":"M Weinblatt","year":"2006","unstructured":"Weinblatt M, Combe B, Covucci A et al (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54:2807\u20132816","journal-title":"Arthritis Rheum"},{"key":"2303_CR31","first-page":"256","volume":"23","author":"WHO","year":"1969","unstructured":"WHO (1969) The evaluation of drugs: whose responsibility? IOMS Round Table Conference, October 1968. WHO Chron 23:256\u2013263","journal-title":"WHO Chron"},{"key":"2303_CR32","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christenses R et al. (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 16;2:CD008794","DOI":"10.1002\/14651858.CD008794.pub2"},{"issue":"Suppl 3","key":"2303_CR33","first-page":"386","volume":"69","author":"JE Gottenberg","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T et al (2010) Prospective follow-up of abatacept treatment in 920 patients with refractory rheumatoid arthritis: tolerance and efficacy data from French ORA (Orencia and rheumatoid arthritis) registry. Ann Rheum Dis 69(Suppl 3):386","journal-title":"Ann Rheum Dis"},{"key":"2303_CR34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","volume":"65","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Schiff M, Valente R et al (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis. Arthritis Rheum 65:28\u201338","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2303-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-013-2303-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2303-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T09:40:56Z","timestamp":1563097256000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-013-2303-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,2]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["2303"],"URL":"https:\/\/doi.org\/10.1007\/s10067-013-2303-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,2]]}}}